Drug Profile
Research programme: anticancer antibodies - BioInvent International/University of Southhampton
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator BioInvent International; University of Southampton
- Class Antibodies
- Mechanism of Action Regulatory T-lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer